1. Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021 Jun;21(6):360-378. doi: 10.1038/s41568-021-00346-0. Epub 2021 Apr 27. PMID: 33907315.2. Brown TA 2nd, Mittendorf EA, Hale DF, Myers JW 3rd, Peace KM, Jackson DO, Greene JM, Vreeland TJ, Clifton GT, Ardavanis A, Litton JK, Shumway NM, Symanowski J, Murray JL, Ponniah S, Anastasopoulou EA, Pistamaltzian NF, Baxevanis CN, Perez SA, Papamichail M, Peoples GE. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence. Breast Cancer Res Treat. 2020 Jun;181(2):391-401. doi: 10.1007/s10549-020-05638-x. Epub 2020 Apr 22. PMID: 32323103.3. Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, Hale DF, Perez SA, Anastasopoulou EA, Pistamaltzian NF, Ponniah S, Baxevanis CN, von Hofe E, Papamichail M, Peoples GE. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Ann Oncol. 2016 Jul;27(7):1241-8. doi: 10.1093/annonc/mdw150. Epub 2016 Mar 30. PMID: 27029708.4. McCarthy PM, Clifton GT, Vreeland TJ, Adams AM, O'Shea AE, Peoples GE. AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence. Expert Opin Investig Drugs. 2021 Jan;30(1):5-11. doi: 10.1080/13543784.2021.1849140. Epub 2020 Dec 3. PMID: 33191799.5. Xu M, Kallinteris NL, von Hofe E. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines. Vaccine. 2012 Apr 16;30(18):2805-10. doi: 10.1016/j.vaccine.2012.02.031. Epub 2012 Mar 3. PMID: 22386748.6. Gordon B, Gadi VK. The Role of the Tumor Microenvironment in Developing Successful Therapeutic and Secondary Prophylactic Breast Cancer Vaccines. Vaccines (Basel). 2020 Sep 14;8(3):529. doi: 10.3390/vaccines8030529. PMID: 32937885; PMCID: PMC7565925.7. Buonaguro L, Tagliamonte M. Selecting Target Antigens for Cancer Vaccine Development. Vaccines (Basel). 2020 Oct 17;8(4):615. doi: 10.3390/vaccines8040615. PMID: 33080888; PMCID: PMC7711972.8. Basu A, Ramamoorthi G, Jia Y, Faughn J, Wiener D, Awshah S, Kodumudi K, Czerniecki BJ. Immunotherapy in breast cancer: Current status and future directions. Adv Cancer Res. 2019;143:295-349. doi: 10.1016/bs.acr.2019.03.006. Epub 2019 May 2. PMID: 31202361.